🇺🇸

US SEC Filing Intelligence

· daily

US Material Events SEC 8-K Filings — April 07, 2026

Across 50 filings from April 7, 2026, dominant themes include widespread executive transitions (appointments/resignations in 28 companies, often positive for strategic refresh), a biotech funding surge (e.g., Opus Genetics $155M non-dilutive to 2029 runway, Kiora $24M placement), and liquidity-enhancing maneuvers like sale-leasebacks (New Fortress $266M), asset sales (CVD Equipment $16.9M), and credit facilities (Four Corners $200M term loan). One stark negative: Luminar Technologies Chapter 11 liquidation confirmation signals sector distress in lidar/autonomous tech. Period-over-period data sparse but reveals outliers like Kura Sushi Q2 revenue +23% YoY to $80M, comp sales +8.6%, EBITDA +104% to $5.5M, contrasting Ginkgo Bioworks pro forma 2025 revenue -22% post-Biosecurity divestiture. REIT/industrial financing trends positive with low leverage (Four Corners 5.4x target), while fitness (Xponential strategic review) and tech (WM Technology delisting) show mixed signals amid M&A speculation. Portfolio implication: Favor biotechs with extended runways and monitor leadership churn for conviction shifts.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 07, 2026

The 50 filings for the USA Dow Jones 30 intelligence stream reveal a dominant proxy season theme, with over 25 DEF 14A/DEFA14A filings scheduling virtual annual meetings in mid-May 2026 (e.g., May 19-21), focusing on director elections, auditor ratifications, say-on-pay votes, and plan approvals amid neutral sentiment in most cases. Period-over-period trends show stark contrasts: robust growth in Bread Financial Holdings (net income +87% YoY to $521M, EPS +98% to $10.96), EVERTEC (record 2025 revenue, Latin America expansion), and Global Net Lease (AFFO $0.99/share exceeding guidance, 32% TSR vs peers); offset by collapses like Kaixin Holdings (revenues $31.5M in 2023 to $0 in 2024, losses to $53.9M in 2025) and Phoenix Education (Q2 revenue -0.4% YoY, net income -33% YoY). Capital allocation leans shareholder-friendly with dividends/buybacks (Phoenix $0.21/share div + $50M repurchase; Global Net Lease repurchases amid $2.2B debt cut), while M&A/divestitures provide liquidity (CVD $16.9M SDC sale netting $15M; PROG/P-Squared acquisition). Positive biotech catalysts like Nuvalent's NDA submission contrast liquidity risks (Inotiv covenant waiver). No widespread insider selling/buying patterns, but equity awards signal alignment (Envista CEO 696k shares). Overall, financials/REITs show resilience, biotechs/SPACs offer upside, but select operational distress demands caution.

25 high priority 25 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 07, 2026

Across 50 SEC filings for April 7, 2026, dominant themes include a surge in M&A and de-SPAC activity (e.g., Flushing/OceanFirst merger approvals, Talkspace/UHS, Teamshares/Live Oak), proxy statements signaling annual/special meeting season with mixed comp votes, and SPAC/IPO filings amid biotech financings. Period-over-period trends show mixed results: Crane NXT revenue hit 129% of target ($1,568.6M) but op profit at 79%, CPI Aerostructures revenue declined 14.6% YoY to $69.3M with cash plunging 83.6%, and APEX Tech net loss worsened 371% QoQ to $39K. Financial distress evident in Luminar bankruptcy confirmation and Inotiv liquidity waiver, contrasted by positive capital raises like Opus Genetics' $155M funding and Four Corners' $200M loan. Forward-looking catalysts cluster in Q2 2026 (mergers, earnings like MetLife May 6), with biotech runways extended to 2029. Portfolio-level patterns highlight financial sector consolidation (5+ merger votes), neutral sentiment in 13F holdings (stable ETF-heavy portfolios), and bullish de-SPAC momentum implying alpha in transaction completions.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 07, 2026

Across 50 SEC filings from S&P 500 Consumer Discretionary and related sectors, proxy statements dominate (over 25 DEF 14A/DEFA14A) signaling peak annual meeting season in May 2026, with neutral sentiment but emphasis on governance, director elections, and say-on-pay votes. Period-over-period trends show mixed revenue growth (e.g., UniFirst +3.4% YoY Q2, Jefferies +16.1% YoY) offset by widespread margin compression (UniFirst op income -16.7% YoY, CPI Aerostructures gross profit -38.7% YoY) and operational losses (FG Nexus $40-45M Q1 loss, Skillsoft net loss margin -27.3%). Capital allocation leans shareholder-friendly with buybacks (FG Nexus 2.2M shares at $16.04 avg, UniFirst $32.7M H1) and new debt facilities (Four Corners $200M term loan for Q2/Q3 acquisitions). Mergers advance (Flushing/OceanFirst 97.3% approval) amid strategic reviews (Xponential Fitness exploring sale). Bullish highlights include Target Hospitality's $320.6M FY25 revenue/$0 net debt and Bread Financial's 87% YoY net income surge to $521M; risks from Nasdaq non-compliance (Hydrofarm) and auditor changes. Portfolio-level implication: Selective opportunities in resilient retail/hospitality amid margin pressures, monitor May catalysts for governance shifts.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 07, 2026

Across the 50 filings in the USA S&P 500 Healthcare stream (with broader context from financials and biotechs), proxy season dominates with 20+ DEF 14A/DEFA14A filings scheduling May 2026 AGMs, emphasizing governance, director elections, say-on-pay (mixed support at Thermo Fisher), and auditor ratifications. Healthcare-specific trends show resilient large-cap performance (Amgen +10% YoY revenue, record 18 product sales) contrasted by small-cap biotech volatility: positive catalysts like Pulse Biosciences' pivotal trial enrollments and TriSalus CMO promotion, offset by Protagenic CFO exit and NovaBridge's 83% wider operating losses ($94.3M). Capital allocation remains shareholder-friendly with Amgen's $5B dividends/$6B debt reduction, Jackson Financial's 12.5% dividend hike/$1B buyback expansion, and Cintas' $933M repurchases amid 8.9% YoY revenue growth. Merger approvals (Flushing 97.3% yes, OceanFirst issuance approved) signal M&A momentum in adjacents, while Nasdaq compliance regains (Artelo, Tianci) aid biotechs. No major guidance cuts; forward catalysts cluster in May AGMs and clinical milestones (Pulse 6/12-month endpoints). Overall, bullish large-cap stability vs. high-beta biotech risks, with portfolio-level revenue growth averaging +10-16% YoY where reported, but margin pressures in mixed sentiment filings.

25 high priority 25 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 07, 2026

Across 50 DEF 14A filings for US companies' 2026 annual meetings (primarily May 19-21), a dominant theme is robust 2025 fiscal performance with 14 companies explicitly reporting YoY revenue growth (avg +28%, range 4%-98%) in sectors like transport/logistics (XPO +LTL EBITDA 4% YoY), airlines (United +7.3% pre-tax margin), pharma (Collegium +48% Jornay PM), and fintech (Bread Financial net income +87% YoY), signaling broad economic resilience despite isolated challenges. Neutral sentiment prevails (32/50), with positive in 12 (e.g., Target Hospitality $0 net debt, Global Net Lease 32% TSR) and mixed in 2; no explicit guidance cuts but forward-looking catalysts include auditor ratifications for FY2026, equity plan expansions (e.g., Mistras +1.7M shares), and PDUFA dates (INOVIO Oct 2026). Capital allocation leans shareholder-friendly with buybacks (Collegium $25M, Rush $193.5M), dividends (Rush +5.6%), and debt reduction (Global Net Lease $2.2B), though dilution risks from incentive plan increases in 5 firms. Portfolio-level trend: 8/14 reporting firms show margin stability/improvement (e.g., XPO LTL +80bps), outperforming peers; sector patterns favor transport/pharma over REITs/funds. Market implication: Buy dips in high-performers pre-May meetings for potential say-on-pay catalysts and TSR boosts.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 07, 2026

The IPO Pipeline stream reveals two high-materiality S-1 filings on April 7, 2026, signaling renewed capital market activity in SPACs and biotech: RRE Ventures Acquisition Corp. launching a 25M-unit IPO and Artelo Biosciences registering 9.8M shares for resale post-$11M private placement. Both exhibit positive sentiment, with Artelo showcasing key turnaround metrics including a 1-for-3 reverse split reducing outstanding shares 65% YoY (2.12M to 736k), full repayment of $665k bridge notes, and Nasdaq compliance regained on April 6 after meeting $2.5M equity threshold. No direct revenue/margin period-over-period trends available due to pre-revenue SPAC and development-stage biotech status, but Artelo's debt reduction and share reduction highlight deleveraging efforts. Cross-filing themes include warrant-heavy structures (RRE: 15.3M warrants at $11.50; Artelo: 6.4M common + 3.1M pre-funded at $3.20), founder/sponsor commitments, and dilution risks, positioning these as speculative plays in a potentially thawing IPO market. Market implications favor tactical positioning ahead of IPO effectiveness and trading launches, with Artelo's compliance as a near-term catalyst.

2 high priority 2 total filings
· daily

Global High-Priority Regulatory Events — April 07, 2026

Across 50 filings from April 7, 2026, the dominant theme is the 2026 proxy season with 15+ DEF 14A filings scheduling annual meetings in May 2026 for director elections, say-on-pay votes, and auditor ratifications, signaling routine governance amid mixed 2025 performances. SPAC and de-SPAC activities proliferate (e.g., Legato extension, Live Oak S-4, Energy Transition S-1 IPO), alongside M&A momentum in financials (Flushing/OceanFirst approvals, CVB/Heritage contingent) and acquisitions (Brink’s/NCR Atleos financing). Biotech/pharma shows resilience with financings (Kiora $24M, Opus $155M, GT Biopharma trial) offsetting distress (Luminar bankruptcy confirmation, Protagenic CFO exit, Cell Source going concern). Period-over-period trends reveal revenue declines in tech/infra (Cambium -21.8% YoY, Jaguar -1.5% YoY) contrasted by outperformers (Bread Financial net income +87% YoY, Target Hospitality $320M revenue). Indian filings highlight promoter encumbrance risks (new pledges in Choice/Ideaforge, releases in Paisalo). Capital allocation leans toward equity incentives (Mistras +1.7M shares) and debt raises (Four Corners $200M loan), with forward catalysts like Adani Power earnings Apr 29 and SPAC closings Q2 2026. Overall, actionable alpha in M&A/SPAC mergers and biotech funding, but watch distress signals in biotechs and Indian pledges.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 07, 2026

Across 17 filings, results reveal a bifurcated market with resilient services and financial firms (e.g., Cintas +8.9% YoY revenue, Jefferies +16.1%) offsetting declines in manufacturing/tech (Greenbrier -23% YoY, Cambium -21.8%) and biotechs (Jaguar Health losses widening 37.6% YoY), yielding aggregate revenue growth near flat but with margin volatility (improvements in Cambium +160 bps gross margin, compressions in UniFirst op income -16.7%). Capital allocation leans shareholder-friendly via buybacks (Cintas $933M YTD, UniFirst $33M H1) and dividends (Greenbrier $0.64/share, Phoenix $0.21/share), though cash burn persists in early-stage firms (Cell Source going concern doubt, Thunder Power cash to $10K). SPACs show IPO strength (APEX trust $112M), while education peers struggle (Skillsoft flat revenue, Phoenix net income -58%). Forward-looking catalysts cluster in biotech milestones (Cell Source Phase 2 by 2028), with no major guidance changes but elevated risks from impairments (Cambium $25.5M, Skillsoft 6.2% of rev). Portfolio implication: Favor services/consumer outperformers amid cyclical weakness, monitor cash flows for 9 mixed-sentiment names.

17 high priority 17 total filings
· daily

US SEC Trading Suspension Halt Orders — April 07, 2026

Across five small-cap filings in the USA Trading Suspensions stream, a dominant theme is Nasdaq non-compliance with Listing Rule 5550(b)(1) due to severe stockholders’ equity deficits (HYFM -$63.3M, Direct Digital -$7.0M as of Dec 31, 2025), alongside bid price issues (Tianci resolved), NYSE filing delays (Genie), and voluntary delisting (WM Technology). Negative sentiment prevails in 4/5 cases (materiality 9-10/10), signaling heightened delisting risks and potential trading halts, with no period-over-period financial improvements noted to reverse deficits QoQ into Q1 2026. Forward-looking catalysts cluster in April-May 2026, including compliance plans (HYFM May 16), hearings (Direct Digital by Apr 9), and delisting (WM ~Apr 24), implying immediate liquidity erosion on US exchanges. No insider trading activity reported across filings, but persistent deficits vs required $2.5M minimum highlight capital allocation failures and operational distress. Portfolio-level pattern: 80% of companies face imminent regulatory cliffs, favoring short/avoid strategies for Nasdaq small caps amid no YoY equity recovery trends.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 07, 2026

In the USA Corporate Distress & Bankruptcy intelligence stream spanning 29 filings (22 new), a bifurcated landscape emerges: acute distress in 6 cases including Luminar Technologies' confirmed Chapter 11 liquidation plan, Nasdaq delisting threats for Hydrofarm (-$63M equity deficit) and Direct Digital (-$7M deficit), Americas CarMart closing 42/136 stores with $14M impairment, Genie Energy's NYSE noncompliance from delayed 10-K restatements, and WM Technology's voluntary Nasdaq delisting; contrasted by 12 positive liquidity events averaging ~$60M each, notably Opus Genetics' $155M non-dilutive funding extending runway to 2029, Kiora Pharmaceuticals' $24M placement, Four Corners Property Trust's $200M loan at 5.4x leverage, and New Fortress Energy's $266M sale-leaseback. No widespread period-over-period declines reported across filings, but equity deficits highlight small-cap balance sheet frailties vs minimum thresholds ($2.5M Nasdaq). Biotech sector shines with 4/5 filings showing funding/runway extensions amid clinical catalysts (e.g., OPGx-BEST1 topline mid-2026), while energy/REITs amend/extend debt facilities positively. Capital allocation leans toward debt raises over returns, with no dividends/buybacks noted; insider activity sparse but Boxlight's related-party conversion flags potential conflicts. Forward-looking catalysts cluster in Q2 2026 (trials, closings, compliance deadlines), signaling near-term volatility for distressed names but alpha in turnarounds.

29 high priority 29 total filings
· daily

US Executive Officer Management Changes SEC — April 07, 2026

Across 36 filings on April 7, 2026, executive and director changes dominate with 24 appointments/promotions (e.g., new CEOs at ATN, Duos; CFOs at Velo3D, PSQ; board adds in biotech/pharma like Abeona, Stoke, TriSalus) outpacing 14 resignations/step-downs (e.g., CFO terminations at Protagenic, AB Intl; retirements at Levi, Mattel), signaling broad leadership refreshment and stability via planned transitions in 70% of cases. Financial enriched data sparse but highlights Kura Sushi Q2 FY2026 sales +23.3% YoY to $80M, comp sales +8.6% (4.3% traffic/price), Adj EBITDA +103.7% to $5.5M, restaurant margins +90bps to 18.2%, FY guidance $333-335M (16 new units); Capital One completed $2.56B Brex acquisition with special $2M RSU to exec. No portfolio-wide margin compression (only Kura food costs +170bps YoY due to tariffs); equity-heavy comp (RSUs/PSUs in Velo3D, ADTRAN, Kaival) aligns management, while salary hikes (Unusual Machines + to $350k CEO) imply minor cost pressures. Sector patterns: biotech/pharma (8/36) adding audit/med experts amid catalysts (Corbus ASCO May 2026); telecom/real estate (ATN, Ares) CEO/board shifts for growth. Net positive sentiment (18 positive/mixed-positive vs 3 negative), high materiality in CEO/CFO changes (avg 7.5/10); actionable: favor smooth transitions, watch sudden exits for volatility.

36 high priority 36 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — April 07, 2026

The USA Bankruptcy & Insolvency intelligence stream highlights a single critical filing from Luminar Technologies, Inc., where the U.S. Bankruptcy Court for the Southern District of Texas confirmed the Fourth Amended Chapter 11 Plan of Liquidation on April 3, 2026, following a hearing on April 1, 2026, with all objections overruled. This marks the end of operations as debtors in possession since voluntary petitions filed on December 15 and 31, 2025, under Case No. 25-90807, proceeding directly to asset liquidation with no ongoing business highlighted. No period-over-period financial trends are available in the filing, but the shift to liquidation implies severe prior deterioration in financial health, liquidity, and operational viability. Sentiment is uniformly negative (10/10 materiality), signaling total equity wipeout risk and creditor priority in distributions. Portfolio-level theme across 1/1 filings: acceleration of tech sector insolvencies into structured liquidations, bearish for shareholders and bullish for short positions or distressed debt plays. Market implications include imminent delisting pressure, zero recovery for common stock, and potential fire-sale asset opportunities for competitors in lidar/autonomous vehicle tech.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 07, 2026

Across 36 SEC filings on USA Board Room Changes dated April 7, 2026, a surge in C-suite and board transitions dominates, with 22 appointments/promotions (e.g., new CEOs, CFOs, directors) signaling proactive leadership refreshes, contrasted by 14 resignations/step-downs, often amicable and tied to personal reasons or planned successions. Positive sentiment prevails in 14 filings (e.g., expert hires in biotech/finance), neutral in 16, mixed/negative in 6, highlighting sector-specific board strengthening amid strategic pivots like Xponential Fitness' sale review. Limited period-over-period financials show outliers like Kura Sushi USA's Q2 FY2026 revenue up 23.3% YoY to $80M, comp sales +8.6%, but margin pressures from costs (food/bev +170 bps YoY); no broad insider trading patterns, but equity-heavy comp (RSUs, PSUs) in 12 firms indicates alignment. Forward-looking catalysts cluster in biotech (e.g., Corbus ASCO 2026 data, mid-2026 trials) and retail (Kura 16 new units FY2026). Capital allocation tilts to retention via bonuses/salary hikes (e.g., Unusual Machines +$350k CEO salary), with M&A integration (Capital One/Brex). Portfolio implication: Biotech/healthcare shows turnover as growth signal; monitor small-cap finance for stability risks.

36 high priority 36 total filings
· daily

US Merger & Acquisition SEC Filings — April 07, 2026

The April 7, 2026, USA M&A & Takeover Activity stream reveals a robust wave of transaction completions and progressions, with 8 out of 15 filings announcing deal closures including high-profile takeovers (Hologic by Blackstone/TPG at up to $79/share), acquisitions (Runway of SWK boosting assets to $1.2B pro forma), and divestitures (CVD Equipment's SDC sale for $16.9M cash). SPAC activity dominates the first 7 new filings, featuring 5 deadline extensions or combination advancements (Aquaron, Athena, Real Asset-IQM, Alchemy-Cartiga, Haymaker non-redemption), signaling sustained merger momentum amid redemption pressures. Period-over-period pro forma trends show mixed results: revenue declines in Ginkgo (-22% to $132.7M for 2025 post-Biosecurity spin) and TCW Direct Lending (-70% NII to $30M), contrasted by Runway's healthcare exposure doubling to 32% and stable NAVs in TCW exchanges. Positive sentiments prevail (9/15 filings), with capital deployed into strategic assets (Supernus psychiatry pipeline, Northwest CDMO), enhancing focus but highlighting profitability challenges in biotech. Portfolio-level implications favor monitoring SPAC catalysts for de-SPAC pops and post-merger integration risks in finance/healthcare sectors.

15 high priority 15 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 07, 2026

Overnight SEC filings reveal a surge in M&A and SPAC activity, with 10+ deals progressing including Flushing Financial/OceanFirst merger approvals (97% yes on key vote), Talkspace/UHS merger, Teamshares/Live Oak S-4 filing, and RRE Ventures SPAC IPO of $25M units, signaling consolidation in financials and tech. Period-over-period trends show mixed results: Crane NXT revenue at 129% of 2025 target ($1,568.6M) but op profit at 79%, CPI Aerostructures revenue -14.6% YoY to $69.3M with net loss vs prior income, APEX Tech net loss worsened 371% QoQ to $39k, while MetLife prelim Q1 variable income $475-525M ahead of full-year $1.6B guide. Biotech shines with Opus Genetics $155M non-dilutive funding extending runway to 2029 and Starton Holdings S-1/A for IPO, but Luminar Technologies confirmed Chapter 11 liquidation plan marks a major casualty. Capital allocation leans positive with Four Corners $200M term loan for acquisitions at 200+ bps spreads and News Corp $1B buyback authorization. Proxy season ramps up with mixed say-on-pay votes (e.g., Flushing narrow 50% pass) and Janus Henderson merger supplements detailing competing bids up to $52/share. Overall, bullish M&A momentum outweighs isolated distress signals, with catalysts clustered in Q2 2026.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 06, 2026

Across 17 filings from S&P 500 Technology and adjacent sectors, proxy season dominates with 10 DEF/DEFA14A filings signaling upcoming May 2026 annual meetings, featuring mixed executive comp outcomes and governance votes amid neutral sentiment. Core tech names like ServiceNow, Broadcom, Oracle, and CrowdStrike drive bullish themes with robust 2025 performance (e.g., ServiceNow's 21% YoY subscription revenue growth to $12.8B, 31% non-GAAP op margin), strategic AI deals extending to 2031, C-suite appointments during high-growth phases, and expanded $1.5B share repurchases. Period-over-period trends show strength in software/cloud (ServiceNow +31% total rev YoY, Rule of 56) contrasted by real estate proxies' mixed comp (MAA Core FFO beat but SS NOI miss -1.36% vs -1.15% target). Positive leadership changes at Oracle, Veradigm, and Murphy USA indicate stabilization/turnaround efforts, while Broadcom's Google TPU deal positions it for long-term AI compute dominance. Portfolio-level, 4/5 key tech filings bullish on growth/capital returns, but high debt in Madison Air ($3.98B, 68% of op cash flows) flags leverage risks; implications favor overweighting software leaders ahead of catalysts.

10 high priority 7 medium 17 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 06, 2026

Across 13 NASDAQ-100 related filings dated April 6, 2026, proxy season dominates with 7 DEF/DEFA14A filings highlighting annual meetings in May 2026, mixed executive compensation outcomes, and governance updates amid stable but unremarkable sentiment. Real estate firms like MAA and AvalonBay show mixed performance with MAA beating Core FFO ($8.77 vs $8.74 target) and FAD ($696M vs $685M) but missing SS NOI (-1.36% vs -1.15%) and 3-yr TSR (-1.47% vs 4.07%), while audit fees declined 13% YoY to $2.48M. Leadership transitions are positive, including permanent CFO appointments at Veradigm and Murphy USA, Cisco's board refresh, and Broadcom's blockbuster AI deals with Google (TPUs to 2031) and Anthropic (3.5GW capacity from 2027). Madison Air Solutions' S-1/A reveals sharp operating cash flow growth (+118% YoY to $480M) but high debt service ($549M, 68% of ops cash) and material control weaknesses pre-IPO. Portfolio-level trends include neutral-to-mixed sentiment (avg materiality 6.5/10), no insider trading signals, limited capital returns data, and a catalyst cluster of May shareholder meetings; implications favor monitoring real estate comp votes and AI supply chain momentum for near-term volatility.

8 high priority 5 medium 13 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 06, 2026

Across 50 filings in the USA S&P 500 Financials intelligence stream (despite some cross-sector inclusions), dominant themes include a surge in proxy materials for May 2026 annual meetings (e.g., Schwab, MAA, Genworth, JPM), signaling routine governance but with positive comp approvals; robust M&A activity (Neurocrine-Soleno $2.9B, Profusa LOI $30M stock); mixed financial trends with JPM's record $185.6B revenue/17% ROE contrasting Airsculpt's -15.8% YoY revenue drop to $151.8M and widened net loss to -$11.7M; SPAC/IPO filings highlighting dilution risks. Period-over-period, 4/10 with revenue data show declines averaging -12% YoY (Airsculpt -15.8%, Laird +24% outlier), while JPM/Middlesex post strong growth; capital allocation leans to dividends (Middlesex 53-year streak) and buybacks absent. Forward-looking catalysts cluster in May meetings and Q2 deals, with guidance stable/positive (Airsculpt FY26 $151-157M revenue). Portfolio implication: Financials like JPM/Schwab exhibit strength amid sector proxy normalization, but watch M&A dilution and revenue softness in adjacent names.

25 high priority 25 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 06, 2026

Across 40 SEC filings in the USA S&P 500 Consumer Staples intelligence stream (encompassing food/beverage like Krispy Kreme/McCormick alongside broader market filings), key themes include widespread board refreshments and leadership transitions (12+ instances, e.g., Krispy Kreme adding Kraft Heinz alum, Tapestry Pinterest CTO), accelerating M&A (McCormick-Unilever SpinCo tax-free merger, Clear Channel Mubadala-backed deal), and mixed financial trends with average reported revenue growth of +5.8% YoY (iQSTEL +11.9% to $317M, NewtekOne volumes +7% implied, offset by Tsakos -0.7%, Elvictor +0.3%). Margin trends show slight improvement where noted (iQSTEL gross +72bps to 3.46%), but op ex pressures (Elvictor +19%). Forward-looking data clusters catalysts in late April-May 2026 (10+ AGMs/earnings). No major insider buys/sells, but separations (Krispy CPO, DeFi CCO) and capital allocation via share issuances/dilutive debt amendments (Bright Mountain 2.9M shares). Sentiment positive/neutral in 70%, mixed in 25%; actionable: Buy growth catalysts like NewtekOne, avoid debt restructurings. Portfolio implication: Staples governance strengthening amid modest growth, M&A upside for McCormick.

16 high priority 24 medium 40 total filings